Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely

Immutep shares update on Phase I study of LAG-3 agonist antibody for autoimmune diseases, showing positive safety & efficacy ...

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable ...

Clinical trial of potential diabetes and arthritis treatment delivers positive results

Immutep has announced positive phase one trial results for a compound that could help treat autoimmune diseases.
Investopedia

Understanding Capital Injections: Definition and Key Examples

Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. David Kindness is a Certified Public Accountant (CPA) and an ...
Taiwan News

Novel Vaccine Delivery Systems Market Forecast 2030 Global Industry Expected to Reach US$ 11.3 Billion, Growing at a CAGR of 9.8% (2022–2030)

The global novel vaccine delivery systems market size was US$ 5,429.6 million in 2021. The global novel vaccine delivery systems market is forecast to grow to US$ 11,306.1 million by 2030 by ...